Guest Editor(s)

• Prof. Thomas Efferth

  Director, Institute of Pharmaceutical and Biomedical Sciences; Chair, Department of Pharmaceutical Biology, Johannes Gutenberg University, Mainz, Germany.

  Website | E-mail

• Prof. Sanjay Gupta

  Department of Urologic Oncology, Case Western Reserve University, Cleveland, OH, USA.

  Website | E-mail

Special Issue Introduction

Metastatic castration-resistant prostate cancer (mCRPC) is the most lethal, progressive, and incurable form of prostate cancer. Currently approved systemic therapies include cytotoxic drugs (docetaxel and cabazitaxel), AR-targeted therapies (enzalutamide and abiraterone), PARP (poly(ADP)-ribose polymerase) inhibitors (olaparib and niraparib), radioisotope radium-223 and several other therapies are able to increase survival of mCPRC patients. Unfortunately, despite the demonstrated benefit, not all patients respond to treatment and almost all are destined to develop resistance to these therapies. The special issue on "Drug Resistance in Metastatic Castration-Resistant Prostate Cancer" is soliciting original research articles, reviews and commentaries updating the problem of drug resistance in the treatment of mCRPC and mitigate these effects through evidence or laboratory-based research. The special issue will also include research articles presenting novel outstanding data on all aspects of drug resistance mechanisms in mCRPC. Better understanding of the drug resistance mechanisms, and targeting new pathways will hopefully change the treatment paradigm.

Submission Deadline

1 Oct 2021

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://cdrjournal.com/pages/view/author_instructions
For Online Submission, please login at https://oaemesas.com/CDR/?IssueId=698
Submission Deadline: 1 Oct 2021
Contacts: Bella Zhao, Assistant Editor, bella@cdrjournal.com